Company Description
Davion Healthcare Plc, a digital healthcare company, engages in the design, development, and commercialization of non-invasive health monitoring technologies.
Its core consumer health portfolio comprises proprietary, home-based monitoring devices designed to support the early identification of potential medical anomalies.
The company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature.
It is also developing a portfolio of proprietary health monitoring technologies, including FootFlow for monitoring indicators associated with circulation and diabetes-related blood flow issues; Testic, an at-home testicular health monitoring system; and ThermaDerm for the identification of skin anomalies, as well as technologies addressing wound monitoring, blood pressure, and other areas of preventive healthcare.
The company was incorporated in 2022 and is based in Cork, Ireland.
| Country | Ireland |
| Founded | 2022 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| CEO | Glenn Williams |
Contact Details
Address: West Cork Business & Technology Park, Unit A Cork, P85 FV48 Ireland | |
| Phone | 353 238 808 958 |
| Website | davionhealthcare.com |
Stock Details
| Ticker Symbol | DAVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $12.00 |
| CIK Code | 2039072 |
| ISIN Number | IE000GVCI8S8 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Glenn Williams | Chief Executive Officer |
| Andreas Ttofi | Chief Financial Officer |
| Jeremy North | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 9, 2026 | 6-K | Report of foreign issuer |
| Nov 9, 2026 | 6-K | Report of foreign issuer |
| Oct 29, 2026 | 6-K | Report of foreign issuer |
| Oct 27, 2026 | 6-K | Report of foreign issuer |
| Oct 21, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 20, 2026 | 424B3 | Prospectus |
| Oct 20, 2026 | 6-K | Report of foreign issuer |
| Oct 13, 2026 | 424B3 | Prospectus |
| Sep 15, 2026 | 6-K | Report of foreign issuer |
| Sep 8, 2026 | D | Notice of Exempt Offering of Securities |